JP2016516400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516400A5 JP2016516400A5 JP2015561931A JP2015561931A JP2016516400A5 JP 2016516400 A5 JP2016516400 A5 JP 2016516400A5 JP 2015561931 A JP2015561931 A JP 2015561931A JP 2015561931 A JP2015561931 A JP 2015561931A JP 2016516400 A5 JP2016516400 A5 JP 2016516400A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- antigen
- binding fragment
- protein
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 241000725643 Respiratory syncytial virus Species 0.000 claims 5
- 241000699666 Mus <mouse, genus> Species 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310082338 | 2013-03-15 | ||
| CN201310082338.1 | 2013-03-15 | ||
| PCT/CN2014/073505 WO2014139476A1 (zh) | 2013-03-15 | 2014-03-17 | Rsv融合蛋白的表位以及识别其的抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516400A JP2016516400A (ja) | 2016-06-09 |
| JP2016516400A5 true JP2016516400A5 (enExample) | 2017-03-30 |
| JP6462599B2 JP6462599B2 (ja) | 2019-01-30 |
Family
ID=51535878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561931A Active JP6462599B2 (ja) | 2013-03-15 | 2014-03-17 | Ｒｓｖ融合タンパク質のエピトープ及びそのエピトープを認識する抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9856313B2 (enExample) |
| EP (1) | EP2975052B1 (enExample) |
| JP (1) | JP6462599B2 (enExample) |
| CN (1) | CN105722856B (enExample) |
| AU (1) | AU2014231357B2 (enExample) |
| CA (1) | CA2906960C (enExample) |
| WO (1) | WO2014139476A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| AU2014243756B2 (en) | 2013-03-13 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| CN106496324B (zh) * | 2015-11-30 | 2020-01-14 | 天津昊免生物技术有限公司 | 一种抗呼吸道合胞病毒的全人源抗体 |
| KR20220041966A (ko) * | 2016-04-05 | 2022-04-01 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 용해성 융합-전 rsv f 단백질 |
| JP2020503844A (ja) * | 2016-10-21 | 2020-02-06 | アディマブ， エルエルシー | 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法 |
| KR20240128132A (ko) * | 2016-10-26 | 2024-08-23 | 세다르스-신나이 메디칼 센터 | 중화 항-tl1a 단일 클론 항체 |
| EP3554545A4 (en) * | 2016-12-19 | 2020-08-12 | Vanderbilt University | ANTIBODIES DIRECTED AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS PRE-FUSION PROTEIN CONFORMATION AND THEIR USE METHODS |
| CN108265079A (zh) * | 2017-01-02 | 2018-07-10 | 刘昕 | 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法 |
| CN113832116B (zh) * | 2017-01-12 | 2024-09-13 | 厦门大学 | 稳定呼吸道合胞病毒融合蛋白的方法 |
| JP7168938B2 (ja) | 2017-04-04 | 2022-11-10 | ユニヴァーシティ オブ ワシントン | パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用 |
| CA3095216A1 (en) | 2018-02-28 | 2019-09-06 | University Of Washington | Self-asssembling nanostructure vaccines |
| CN110684747B (zh) * | 2018-07-06 | 2024-05-24 | 厦门大学 | 灭活及保存呼吸道合胞病毒的方法 |
| CN111057718A (zh) * | 2018-10-17 | 2020-04-24 | 南京大学 | 一种稳定表达绿色荧光蛋白的egfp-sp2/0细胞株及其构建方法 |
| CN113543803B (zh) * | 2019-02-28 | 2024-10-29 | Km生物医药股份公司 | Rsv f/g嵌合疫苗 |
| WO2021242294A1 (en) * | 2020-05-28 | 2021-12-02 | Sotira Covid, Llc | Peptides for covid-19 prevention and treatment |
| WO2022268120A1 (en) * | 2021-06-22 | 2022-12-29 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-rsv antibodies and uses thereof |
| AU2022404234A1 (en) * | 2021-12-06 | 2024-05-09 | Xiamen University | Antibody for recognizing rsv pre-f protein and use thereof |
| CN116478296B (zh) * | 2022-10-17 | 2024-02-23 | 厦门大学 | 截短的呼吸道合胞病毒f蛋白及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| EP1997830A1 (en) * | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| US8568726B2 (en) * | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| JP5734988B2 (ja) | 2009-10-06 | 2015-06-17 | メディミューン リミテド | Ｒｓｖ特異的結合分子 |
| NZ703035A (en) * | 2010-07-09 | 2016-06-24 | Crucell Holland Bv | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
| CN102210860B (zh) * | 2011-05-31 | 2012-11-21 | 昆明理工大学 | 一种结核分枝杆菌tb10．4-f1融合蛋白疫苗及制备方法 |
-
2014
- 2014-03-17 AU AU2014231357A patent/AU2014231357B2/en active Active
- 2014-03-17 EP EP14765573.2A patent/EP2975052B1/en active Active
- 2014-03-17 CA CA2906960A patent/CA2906960C/en active Active
- 2014-03-17 CN CN201480013927.7A patent/CN105722856B/zh active Active
- 2014-03-17 WO PCT/CN2014/073505 patent/WO2014139476A1/zh not_active Ceased
- 2014-03-17 US US14/777,275 patent/US9856313B2/en active Active
- 2014-03-17 JP JP2015561931A patent/JP6462599B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516400A5 (enExample) | ||
| JP2015511817A5 (enExample) | ||
| JP2018521638A5 (enExample) | ||
| JP2020535799A5 (enExample) | ||
| IL273196B2 (en) | Claudin6 antibodies and methods of treating cancer | |
| JP2021500916A5 (enExample) | ||
| JP2020536488A5 (enExample) | ||
| JP2019054802A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| RU2016129274A (ru) | Канинизированные мышиные антитела к человеческому pd-1 | |
| JP2013198490A5 (enExample) | ||
| JP2018504105A5 (enExample) | ||
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
| JP2009225799A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| JP2017149720A5 (enExample) | ||
| RU2017114341A (ru) | Антитела к pd-l1, связывающие pd-l1 собаки | |
| JP2014511179A5 (enExample) | ||
| JP2018516853A5 (enExample) | ||
| JP2011173884A5 (enExample) | ||
| JP2012010714A5 (enExample) | ||
| JP2011527899A5 (enExample) | ||
| US12325739B2 (en) | Bispecific SARS-CoV-2 antibodies and methods of use | |
| JP2010516229A5 (enExample) |